1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

340B Providers Offer Varying Approaches To Tracking, Using Discounts At Hearing

 
• By Cathy Kelly

House Energy and Commerce Committee Chair Greg Walden, R-Ore., expresses frustration at lack of reliable data on the way providers account for 340B drug discounts at Oct. 11 hearing.

Capitol House

Hospitals and other health care providers participating in the 340B drug discount program use different approaches to tracking how much they receive in 340B savings and how those savings are used, which points to the need for greater transparency, House Energy and Commerce Committee Chairman Greg Walden, R-Ore., said at an Oversight Subcommittee hearing on the program Oct. 11.

"The lack of transparency requirements has resulted in inconsistent data and dueling reports from every side of the issue," Walden...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

‘Urgent Need’ To Scale Up Advice Slots Under EU HTA Regulation – EUCOPE

 
• By Eliza Slawther

European regulators could investigate alternative ways of offering early advice to companies in relation to the Health Technology Assessment Regulation, given that official scientific advice slots are limited, a senior figure at EUCOPE says.

Oz Hints That Medicare Action On GLP-1s And Weight Loss Coming

 
• By Sarah Karlin-Smith

CMS Administrator Oz punted on a GLP-1 question in an interview, suggesting it was because his agency will be acting soon.

GLOBE Medicare Pricing Model: MFN Bargaining Chip Or Part Of Broad Reform Agenda?

 
• By Cathy Kelly

For manufacturers, the model could lead to a substantial reductions in prices for high cost physician administered drugs in Medicare, Medicaid and the 340B program.

US Tariffs And Geopolitical Tensions Push EU To New Trade Routes And Infrastructure Growth

 
• By Francesca Bruce

The EU is diversifying its trading partners, which means that new markets may open up to the pharmaceutical industry, countering transatlantic tensions.

More from Market Access

US Tariffs And Geopolitical Tensions Push EU To New Trade Routes And Infrastructure Growth

 
• By Francesca Bruce

The EU is diversifying its trading partners, which means that new markets may open up to the pharmaceutical industry, countering transatlantic tensions.

Pink Sheet Podcast: Government Shutdown’s Impact On US FDA, Pfizer Inks Drug Pricing Deal

 
• By Derrick Gingery, Sarah Karlin-Smith, Cathy Kelly, and Sue Sutter

Pink Sheet reporter and editors discuss the issues that could arise for the FDA as it navigates the government shutdown, as well as the aftershocks of Pfizer’s drug pricing deal with the White House.

Most Drug Firms Fail To Comply With Key EU HTA Step, EMA Warns

 
• By Eliza Slawther

More than half of drug marketing authorization applicants whose products fell within the scope of the Health Technology Assessment Regulation this year failed to communicate with the HTA Secretariat as required, a senior figure at the European Medicines Agency says.